

⁵
~~24.~~ The composition of Claim ~~24~~² wherein the alkanoic acid is octanoic acid, decanoic acid, dodecanoic acid, or tetradecanoic acid.

B2
Continued
⁶
~~25.~~ The method of Claim ~~25~~³ wherein the alkanoic acid is octanoic acid, decanoic acid, dodecanoic acid, or tetradecanoic acid.


REMARKS

This application is directed to the C₂₋₂₀alkanoic acid esters of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, to pharmaceutical compositions containing the same, and to a method of treating warm-blooded mammals suffering from psychotic diseases by administering the same. The claimed compounds are the C₂₋₂₀ alkanoic acid esters of 9-hydroxyrisperidone, that is, those compounds of Formula (I) wherein R¹ = 6-fluoro, R² = 2-methyl, R³ = R⁴-C(=O)O- wherein R⁴ = C₁₋₁₉alkyl, and Alk = ethanediyl. The sub-generic claims are directed to the compounds, composition and method-of-use wherein the alkanoic acid is octanoic acid, decanoic acid, dodecanoic acid, or tetradecanoic acid, as recited in original Claims 5, 11 and 17.

JAB 828

Early favorable action on the merits of this application is respectfully requested.

Respectfully submitted,


Charles J. Metz
Attorney for Applicants
Registration #20,359

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933

(908) 524-2814

August 19, 1992